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Background: The National Cardiovascular Disease (NCVD) Database Registry represents one of the first prospective,
multi-center registries to treat and prevent coronary artery disease (CAD) in Malaysia. Since ethnicity is an important
consideration in the occurrence of acute coronary syndrome (ACS) globally, therefore, we aimed to identify the role
of ethnicity in the occurrence of ACS among high-risk groups in the Malaysian population.
Methods: The NCVD involves more than 15 Ministry of Health (MOH) hospitals nationwide, universities and the
National Heart Institute and enrolls patients presenting with ACS [ST-elevation myocardial infarction (STEMI),
non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA)]. We analyzed ethnic differences across
socio-demographic characteristics, hospital medications and invasive therapeutic procedures, treatment of STEMI
and in-hospital clinical outcomes.
Results: We enrolled 13,591 patients. The distribution of the NCVD population was as follows: 49.0% Malays, 22.5%
Chinese, 23.1% Indians and 5.3% Others (representing other indigenous groups and non-Malaysian nationals). The mean
age (SD) of ACS patients at presentation was 59.1 (12.0) years. More than 70% were males. A higher proportion of
patients within each ethnic group had more than two coronary risk factors. Malays had higher body mass index (BMI).
Chinese had highest rate of hypertension and hyperlipidemia. Indians had higher rate of diabetes mellitus (DM) and
family history of premature CAD. Overall, more patients had STEMI than NSTEMI or UA among all ethnic groups. The
use of aspirin was more than 94% among all ethnic groups. Utilization rates for elective and emergency percutaneous
coronary intervention (PCI) and coronary artery bypass graft (CABG) were low among all ethnic groups. In STEMI,
fibrinolysis (streptokinase) appeared to be the dominant treatment options (>70%) for all ethnic groups. In-hospital
mortality rates for STEMI across ethnicity ranges from 8.1% to 10.1% (p = 0.35). Among NSTEMI/UA patients, the rate of
in-hospital mortality ranges from 3.7% to 6.5% and Malays recorded the highest in-hospital mortality rate compared to
other ethnic groups (p = 0.000). In binary multiple logistic regression analysis, differences across ethnicity in the age and
sex-adjusted ORs for in-hospital mortality among STEMI patients was not significant; for NSTEMI/UA patients, Chinese
[OR 0.71 (95% CI 0.55, 0.91)] and Indians [OR 0.57 (95% CI 0.43, 0.76)] showed significantly lower risk of in-hospital
mortality compared to Malays (reference group).
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Conclusions: Risk factor profiles and ACS stratum were significantly different across ethnicity. Despite disparities in risk
factors, clinical presentation, medical treatment and invasive management, ethnic differences in the risk of in-hospital
mortality was not significant among STEMI patients. However, Chinese and Indians showed significantly lower risk of
in-hospital mortality compared to Malays among NSTEMI and UA patients.Background
Acute coronary syndrome (ACS) encompasses a
spectrum of clinical entities, ranging from unstable an-
gina (UA), non-ST-segment elevation myocardial infarc-
tion (NSTEMI) to ST-elevation myocardial infarction
(STEMI) [1]. In the Western world, ACS is the most
common cause of death [2]. Cardiovascular disease
(CVD) mortality is on the rise in the Asia Pacific coun-
tries (including Malaysia) that were undergoing rapid
urbanization, industrialization and lifestyle changes [3].
According to the Global Burden of Disease Study
(GBD), ischemic heart disease (IHD) is ranked first
among the leading causes of mortality for eight regions
in the world [4]. The World Health Organization
(WHO) estimated that CAD will be the single largest
cause of disease burden in many countries world-wide
by the year 2020 [5]. Similarly, in Malaysia, CVD
accounted for 147,843 admissions or about 6.91% of
total admissions in Ministry of Health (MOH) hospitals
in year 2009 [6]. CVD accounted for approximately
24.5% of death in government hospitals in year 2010 and
is the leading cause of death in Malaysia [7].
Established coronary risk factors such as cigarette
smoking, diabetes mellitus (DM), hypertension, obesity,
sedentary life style and dyslipidemias still play major
roles in CAD [8]. While conventional cardiovascular risk
factors such as smoking, blood pressure and total chol-
esterol predict risk within these ethnic groups, they do
not fully account for the differences in risk between eth-
nic groups, suggesting that alternative explanations
might exist [9]. Epidemiological evidence that includes
cross-sectional studies, coronary angiographic studies,
and registry data showed significant differences between
ethnic groups who were diagnosed with ACS in terms of
presentations, risk factors, coronary vessel diameters,
prognoses and outcomes [10-14].
With CVD accounting for most deaths globally, elim-
inating ethnic disparities in cardiac care has become a
new challenge in the practice of cardiology [15]. Studies
have shown that CVDs present differently in between
ethnic groups [16,17]. Ethnicity has been shown to be an
independent predictor of adverse cardiovascular out-
comes in patients with atherothrombotic disease [18]
and CAD [19].
ACS registries are important tools for analyzing dis-
ease management [20,21]. Exploration of registries data
may lead to changes in disease management strategiesand the national health care policies [22]. The National
Cardiovascular Disease (NCVD) Database Registry is
one of the pioneer projects to treat and prevent CAD in
Malaysia. The project is a joint effort of doctors and
nurses in public, private and academic medical ins-
titutions supported by the National Heart Association,
National Heart Foundation, Clinical Research Centre
and the MOH, Malaysia [23].
The aim of this study is, therefore, to identify the role
of ethnicity in relation to the occurrence of ACS among
high-risk groups in the Malaysian population using the
Malaysian NCVD.
Methods
A detailed description of NCVD has been reported else-
where [23,24]. In brief, the NCVD for ACS is the first
prospective, multi-center registry involving more than
15 MOH hospitals nationwide, universities and the
National Heart Institute (IJN: Institut Jantung Negara).
Since its establishment in 2006, all registry centers at-
tempt to ensure the enrollment of an unbiased popula-
tion. The NCVD is an observational prospective registry
that collects data on ‘real-life’ ACS patients comprising
STEMI, NSTEMI and UA according to demographic,
epidemiological, management and outcome characteris-
tics. The registry enrolls inpatients presented with ACS
from January 2006 onwards and is still on-going at the
time of writing.
Entry criteria of ACS include risk stratum of patients
presenting with clinical features consistent with an ACS
(chest pain or overwhelming shortness of breath) and
defined by accompanying clinical, electrocardiographic
and biochemical features. The final diagnosis of ACS
was made by the attending physician using the following
criteria: STEMI was diagnosed on the basis of the pres-
ence of acute chest pain with new or presumably new
ST segment elevations more than 1 mm in two consecu-
tive leads or the presence of a new left bundle branch
block on the index or subsequent ECG with positive car-
diac markers of necrosis [25]. NSTEMI was defined by
ECG ST-segment depression or prominent T-wave in-
version and/or positive biomarkers of necrosis in the ab-
sence of ST-segment elevation and in an appropriate
clinical setting (chest discomfort or angina equivalent).
UA was defined as angina pectoris (or equivalent type of
ischemic discomfort) with any one of the three following
features: a) angina occurring at rest and prolonged,
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least Canadian Cardiovascular Society (CCS) classifica-
tion III severity; c) recent acceleration of angina
reflected by an increase in severity of at least one CCS
class to at least CCS class III. The patient must also have
normal cardiac biomarkers [26].
Demographic, significant risk factors or past medical
history, anthropometric, ACS stratum, treatment, length
of hospitalization, outcome (alive, dead) and complica-
tions (such as bleeding) data were obtained from the
medical records and recorded on a standardized clinical
research form by trained coordinators. Standardized def-
initions for all patient-related variables and clinical
diagnoses were used [24]. Precise definition and quantifi-
cation for risk factors, past medical history and ways of
treatments were described in earlier publications [23,24].
Collected data were subsequently entered into a web-
based centralized database with security password en-
cryption according to individual centers. Regular data
checks were performed and queries were generated for
correction to ensure accuracy. Ethnicity that includes
Malays, Chinese, Indians (major ethnic groups), Indigen-
ous (Orang Asli), Kadazan, Melanau, Murut, Bajau,
Bidayuh, Iban (minor ethnic groups) and other Malay-
sians were recorded. Ethnicity was self-reported and
coded as mutually exclusive categories. We excluded 17
patients with missing ethnic information. A total of
13,591 patients were included in the analysis. The
current study included ACS patients from March 2006
to February 2010 over a period of 4 years. All patients















Figure 1 NCVD recruitment centres (N=13591).Statistical analysis
Data were examined for normality distribution using the
stem-and-leaf plot and Kolmogorov-Smirnov test. De-
scriptive statistics and baseline variables were presented
as numbers and percentages, means and standard devia-
tions, or medians and interquartile ranges. A chi square
test was used to assess differences between categorical
variables; a one-way ANOVA with post-hoc multiple
comparisons (parametric analysis) or Kruskal-Wallis test
(non-parametric analysis) was used to test differences
across the four ethnic groups (Malays, Chinese, Indians,
Others). For multivariate analysis, binary simple and
multiple logistic regressions were used to model the di-
chotomous outcome of STEMI and NSTEMI/UA mor-
tality among ethnic groups with adjustment for age and
sex. We checked for significant interaction between age
and sex and possible multicollinearity by examining the
standard errors of the b coefficients. Any significant
interaction should be included in the final model. Stand-
ard errors of the b coefficients that were less than 2 indi-
cate the absence of multicollinearity. The results were
reported as crude and adjusted odds ratio (OR) with
95% confidence interval for ethnicity. A p value of <0.05
was considered statistically significant. All statistical
calculations were performed using the IBM SPSS
Statistics 20.
Ethics approval
This NCVD study was approved by the Medical Review
& Ethics Committee (MREC), MOH Malaysia in 2007
(Approval Code: NMRR-07-20-250). MREC waived in-
formed consent for NCVD.
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Socio-demographic characteristics
Socio-demographic characteristics and risk factors of the
NCVD population are listed in Table 1. The distribution
of the NCVD population was as follows: 49.0% Malays,
22.5% Chinese, 23.1% Indians, 5.3% Others (representing
other indigenous groups and non-Malaysian nationals)
and 0.1% missing data (Figure 2). The mean age of ACS
patients at presentation was 59.1 (SD 12.0) years. More
than 70% were males (p = 0.000). A large proportion of
individuals within each ethnic group had more than two
coronary risk factors including hypertension, DM and
hyperlipidemia. Majority of patients were overweight
[Body mass index (BMI) of more than 23 kg/m2] in ac-
cordance with the BMI for Asian populations [27].
Malays had the highest BMI (26.0 kg/m2) (p = 0.000).
Indian had the biggest waist circumference (WC)
(90.6 cm), the highest rate of DM (65.2%) and family his-
tory of premature CAD (22.2%) as compared to other
ethnic groups (p = 0.000). Despite having the lowest BMI
(24.8 kg/m2), Chinese had the highest rate of hyperten-
sion (76.1%) and dyslipidemia (51.8%) (p = 0.000). Others
had the highest proportion of current or former smokers
(65.7%) (p = 0.000).
Table 2 shows the ethnic distribution of ACS and clearly
indicated that Others (58.3%) had significantly higher
STEMI (p = 0.000). Overall, more patients had STEMI
than NSTEMI or UA among all the ethnic groups.
Table 3 shows that Malays had significantly higher
mean total cholesterol (TC) and low density lipoprotein
cholesterol (LDL) (5.5 mmol/l, 3.5 mmol/l, respectively)Table 1 Socio-demographic characteristics and risk factors by
Socio-demographic characteristics & risk factors
Malays Ch
Age (SD) (yr) 58.3 (11.5) 62
Men (%) 5230 (78.6) 22
Height (SD) (cm) 161.6 (8.2) 16
Weight (SD) (kg) 68.5 (14.5) 65
WC (SD) (cm) 88.9 (15.4) 86
BMI (SD) (kg/m2) 26.0 (4.4) 24
Smoking (%) 4141 (65.2) 15
Diabetes mellitus (%) 2646 (48.1) 11
Hypertension (%) 3859 (67.4) 20
Dyslipidemia (%) 2104 (48.4) 11
Family history of premature coronary artery disease (%) 725 (15.5) 23
*Others: Indigenous (Orang Asli), Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban (m





BMI: Body Mass Index.
Note: We excluded 17 patients with missing ethnic information.(p = 0.000). Indians had significantly higher mean fasting
blood glucose (FBG) (8.4 mmol/l) (p = 0.000). Troponin
T level was higher among Chinese (1.6 ng/ml). The level
of CK is significantly higher in Others (1242 unit/l)
(p = 0.000).
Hospital medications
Medication use at the time of admission is listed in
Table 4. Aspirin, adenosine diphosphate antagonist, β-
blockers, angiotensin-converting enzyme inhibitors, and
statins were commonly prescribed to all ACS patients.
The use of antiplatelet therapies, such as aspirin, was
similar among all ethnic groups; more than 94% of pa-
tients in each group were taking aspirin at baseline.
Malays received significantly lower proportion of low
molecular weight heparin (LMWH) than other ethnic
groups (p = 0.000).
Invasive therapeutic procedures
Majority of patients in the registry were recorded in cen-
ters with on-site cardiac catheterization facilities and
teaching hospitals (Figure 1). For ACS patients,
utilization rates for elective and emergency percutaneous
coronary intervention (PCI) (13.1-16.5%) and coronary
artery bypass graft (CABG) (0.7-1.8%) were generally
low among all ethnic groups (Table 5). The overall rates
of invasive therapeutic procedures such as PCI and
CABG were slightly different across the ethnic groups.
Indians and Others (16.5%, 16.5%) were likely to receive
PCI than Chinese and Malays (16.0%, 13.1%) (p = 0 · 000).
CABG rate was slightly higher in Others (1.8%) comparedethnicity
Ethnic group F† χ2‡ df# P§
inese Indians Others*
.9 (12.1) 57.7 (11.9) 56.5 (13.0) 141.2 0.000
05 (72.2) 2275 (72.0) 579 (82.0) 88.7 3 0.000
1.7 (7.6) 162.4 (9.0) 161.3 (8.3) 3.8 0.010
.3 (12.2) 68.5 (14.6) 67.2 (13.6) 24.6 0.000
.9 (13.2) 90.6 (15.4) 86.2 (12.7) 17.0 0.000
.8 (3.7) 25.8 (4.5) 25.5 (4.1) 30.9 0.000
92 (55.1) 1430 (48.7) 439 (65.7) 259.0 3 0.000
47 (45.0) 1780 (65.2) 200 (37.5) 315.9 3 0.000
45 (76.1) 2010 (72.6) 400 (70.1) 73.9 3 0.000
44 (51.8) 1147 (51.2) 193 (42.6) 18.1 3 0.000
5 (11.0) 454 (22.2) 69 (15.5) 101.1 3 0.000










Figure 2 NVCD patients by ethnicity.
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respectively (p = 0.006). Left anterior descending (LAD)
artery was the commonest culprit artery involved in ACS
among all ethnic groups followed by right coronary artery
(RCA) and left circumflex (LCX) artery. However, the
difference across the ethnic groups was not significant
(p = 0.359).
Treatment of STEMI
Table 6 shows the reperfusion strategy for STEMI in-
cluding subgroup analysis for the fibrinolytic group,
door-to-needle time and door-to-balloon time. Majority
of STEMI patients (≥80%) received some form of reper-
fusion therapy either by primary PCI or fibrinolysis. Fi-
brinolysis appeared to be the dominant treatment
options (≥70%) for all ethnic groups. Overall, significant
higher proportion of Malays (78.1%) received reperfu-
sion therapy either by primary PCI or fibrinolysis asTable 2 Acute coronary syndrome by ethnicity
ACS stratum Ethnic group
Malays Chinese Indian
STEMI** 3443(51.7) 1286(42.1) 1221(3
NSTEMI*** 1762(26.5) 899(29.4) 972(30
UA**** 1451(21.8) 868(28.4) 952(30
*Others: Indigenous (Orang Asli), Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban (m
**STEMI: ST Elevation Myocardial Infarction.




§P value.compared with other ethnic groups (p = 0.000). Signifi-
cant higher proportion of Chinese (9.0%) received pri-
mary PCI, at the same time, no reperfusion (21.5%) was
higher in Chinese than other ethnic groups (P = 0.000).
In the subset analysis for fibrinolysis, a higher propor-
tion of Malays (8.4%) managed to achieve less than 30 mi-
nutes of door-to-needle time compared to other ethnic
groups (P = 0.000) as recommended by Clinical Practice
Guidelines [25,28]. Others reported higher door-to-needle
time of 59 (IQR: 30–116) min compared to other ethnic
groups (p = 0.013). On the other hand, in primary PCI,
Others had the shortest door-to-balloon time of 81 (IQR:
48–124) min compared to other ethnic groups (p = 0.018).
Overall, it is important to point out that we found a low
percentage of patients achieving less than 30 minutes of
door-to-needle time among all ethnic groups. Further-
more, door-to-needle and door-to-balloon time were lon-
ger than those recommended [25,28].χ2‡ df# P§
s Others*
8.8) 420(58.3) 244 6 0.000
.9) 203(28.2)
.3) 97(13.50)
inor ethnic groups) and other non-Malaysians.
Table 3 Baseline investigation and clinical features on presentation by ethnicity
Baseline investigation & presentation Ethnic group F+ P#
Malays Chinese Indians Others*
TC (mmol/l) 5.5(1.4) 5.1(1.2) 5.1(1.2) 5.3(1.3) 71.2 0.000
LDL (mmol/l) 3.5(1.3) 3.0(1.1) 3.2(1.2) 3.3(1.2) 93.7 0.000
HDL (mmol/l) 1.1(0.3) 1.2(0.4) 1.0(0.3) 1.1(0.3) 53.7 0.000
TG (mmol/l) 2.0(1.8) 2.0(1.2) 2.0(1.3) 2.0(1.1) 2.5 0.057
FBG (mmol/l) 8.0(3.7) 7.5(3.3) 8.4(3.9) 7.4(3.4) 34.7 0.000
Trop T (ng/ml) 1.5(4.6) 1.6(7.1) 1.2(3.6) 1.0(2.0) 1.2 0.300
CK (unit/l) 1075(1484) 884(1322) 789(126) 1242(1583) 36.3 0.000
Heart rate/min 83.1(21.1) 83.1(21.4) 85.9(23.1) 82.7(21.3) 14.1 0.000
SBP (mmHg) 138.9(28.9) 138.9(28.7) 140.2(27.9) 139.6(31.0) 1.8 0.153
DBP (mmHg) 80.9(16.5) 79.9(16.3) 82.2(16.0) 81.3(17.0) 9.7 0.000
Killip Class IV(%)‡ 271(4.1) 100(3.3) 71(2.3) 28(3.9) 15 0.000
LVEF (%)‡ 47(13) 46(13) 47(12) 47(13) 1.5 0.216
*Others: Indigenous (Orang Asli), Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban (minor ethnic groups) and other Malaysians.
+Statistic for one-way ANOVA.
‡No.(%); all others: Mean (SD).
#P value.
TC: Total cholesterol.
LDL: Low density lipoprotein cholesterol.
HDL: High density lipoproteincholesterol.
TG: Triglyceride.
FBG: Fasting blood glucose.
Trop T: Troponin T.
CK: Creatinine kinase.
LVEF: Left ventricular ejection fraction.
Lu and Nordin BMC Cardiovascular Disorders 2013, 13:97 Page 6 of 14
http://www.biomedcentral.com/1471-2261/13/97In-hospital clinical outcomes
Indians reported significantly higher coronary care unit
(CCU) days compared to Malays, Chinese and Others
(3.6, 3.5, 3.2, and 2.5, respectively; p = 0.000) (Table 7).
However, for total days, Malays reported significantly
higher total days of admission compared to Others, In-
dians and Chinese (5.0, 4.9, 4.7, and 4.5, respectively; p
= 0.000). Rates of major bleeding were low (≤ 0.7%)
among all ethnic groups. There was no significant differ-
ence among the ethnic groups in the major or minor
bleeding complication (p = 0.150) according to the
Thrombolysis in Myocardial Infarction (TIMI) criteria
for bleeding [29,30].
In-hospital-mortality rate for STEMI was higher than
NSTEMI and UA among all ethnic groups. STEMI
mortality rate ranges from 8.1 to 10.1% which was statis-
tically insignificant (p = 0.35) across all ethnic groups.
In-hospital mortality was also not significantly different
across ethnic groups in a risk adjusted multivariable
model that controlled for age and sex.
For NSTEMI/UA, there was statistically significant higher
in-hospital-mortality (p = 0.000) among Malays (6.5%) com-
pared to Chinese (5.6%), Others (5.4%) and Indians (3.7%).
These results were persisting after age and sex adjustment.
Therefore, Malays remained a positive predictor for in-
hospital mortality as compared to Chinese and Indians in
the NSTEMI/UA group irrespective of age and sex.Discussion
The study has shown important ethnic differences in the
demographics, comorbid coronary risk factors, clinical
presentation, baseline investigations, treatments and in-
hospital outcomes.
Socio-demographics and coronary risk factors
Malaysia is a multiracial South East Asian country, con-
sisting of 28.3 million people that include 67.4% Malays,
24.6% Chinese, 7.3% Indians, and 0.7% other ethnic
groups [31]. However, the percentage of Indians (major-
ity have their origins in Southern India) captured in this
registry was 23.4% which indicates an over representa-
tion of the Indian population in the NCVD.
It seems that a relatively higher proportion of Indians
was being captured in the NCVD Registry. However, the
causal link between ethnicity and ACS is difficult to evalu-
ate based on cross-sectional data as the NCVD Registry
consists of a well-defined population diagnosed with ACS.
Therefore, based on the NCVD Registry, one cannot pos-
sibly draw any conclusion as to the higher incidence of
ACS among Indians compared to other ethnic groups.
The finding of over-representation of Indians in the
NCVD Registry was an interesting fact that serves as a
basis for a prospective cohort study to reveal the associ-
ation between ethnicity and ACS. Nevertheless, people of
South Asian origin such as India, Pakistan, Bangladesh, Sri
Table 4 Medication use by ethnicity
Medication use Ethnic group χ2** df P#
Malays Chinese Indians Others*
Antiplatelets
Aspirin (%) 6092 (94.4) 2769 (94.1) 2851 (94.2) 649 (95.6) 2.6 3 0.454
Other antiplatelets (%) 4312 (68.5) 2222 (77.0) 2178 (73.0) 440 (73.0) 75.6 3 0.000
Anticoagulants
Heparin (%) 907 (15.0) 202 (7.3) 281 (9.7) 55 (9.8) 128.9 3 0.000
LMWH (%) 3340 (54.1) 1882 (66.2) 2033 (68.6) 435 (68.5) 282.1 3 0.000
Antihypertensives
β-blockers (%) 4238 (67.6) 2052 (71.2) 2067 (69.5) 418 (68.9) 12.3 3 0.060
ACEI (%) 3899 (62.4) 1666 (58.4) 1814 (61.1) 337 (55.9) 19.8 3 0.000
ARB (%) 468 (7.8) 242 (8.7) 304 (10.5) 59 (10.4) 20.3 3 0.000
Diuretics (%) 2016 (32.7) 798 (28.3) 888 (30.2) 196 (33.2) 19.8 3 0.000
CCB (%) 895 (14.8) 409 (14.7) 509 (17.4) 82 (14.5) 12.1 3 0.007
Anti-diabetic agents
OHA (%) 1599 (26.1) 712 (25.4) 1157 (39.3) 112 (19.8) 217.9 3 0.000
Insulin (%) 1522 (24.7) 586 (20.8) 978 (33.1) 104 (18.2) 140.7 3 0.000
Statins
Statins (%) 5833 (91.0) 2700 (92.1) 2737 (90.8) 646 (95.1) 16.6 3 0.001
Categorical variables are expressed as number (%).
*Others: Indigenous (Orang Asli), Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban (minor ethnic groups) and other non-Malaysians.
**Pearson Chi-Square.
#P value.
LMWH: Low Molecular Weight Heparin.
ACEI: Angiotensin Converting Enzyme Inhibitors.
ARB: Angiotensin Receptor Blockers.
CCB: Calcium Channel Blockers.
OHA: Oral Hypoglycemic Agent.
Table 5 Invasive procedures and culprit arteries by ethnicity
Invasive
procedures
Ethnic group χ2‡ df P#
Malays Chinese Indians Others*
PCI (%) 874(13.1) 490(16.0) 518(16.5) 119(16.5) 27.2 3 0.000
CABG (%) 95(1.4) 41(1.3) 21(0.7) 13(1.8) 12.3 3 0.006
LMA involvement (%) 184(2.8) 82(2.7) 84(2.7) 30(4.2) 5.3 3 0.150
Culprit Artery
LAD (%) 591(56.3) 314(56.3) 339(58.0) 81(59.6) 13.1 12 0.359
RCA (%) 318(30.3) 172(30.8) 147(25.2) 37(27.2)
LCX (%) 103(9.8) 53(9.5) 70(12.0) 15(11.0)
LMA (%) 18(1.7) 8(1.4) 8(1.4) 2(1.5)
Bypass graft (%) 20(1.9) 11(2.0) 20(3.4) 1(0.7)
Categorical variables are expressed as number (%).
*Others: Indigenous (Orang Asli), Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban (minor ethnic groups) and other non-Malaysians.
‡Pearson Chi-Square.
#P value.
PCI: Percutaneous Coronary Intervention.
CABG: Coronary Artery Bypass Graft.
LMA: Left Main Artery.
LAD: Left Anterior Descending artery.
LCX: Left Circumflex artery.
RCA: Right Coronary Artery.
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Table 6 Treatment of STEMI by ethnicity
Treatment of STEMI Ethnic Group χ2‡ df# p§
Malays Chinese Indians Others*
No. (%) No. (%) No. (%) No. (%)
Primary PCI 188 (5.6) 111 (9.0) 93 (7.9) 30 (7.4) 40.7 6 0.000
Fibrinolysis 2607 (78.1) 858 (69.5) 878 (74.3) 307 (76.2)
No reperfusion+ 544 (16.3) 265 (21.5) 211 (17.9) 66 (16.4)
Total 3339 (100.0) 1234 (100.0) 1182 (100.0) 403 (100.0)
Fibrinolysis subgroup
Type of fibrinolytic drug used
Streptokinase 1924(97.1) 671(98.0) 661(96.2) 238(97.9) 4.3 3 0.226
Other fibrinolytic drugs 58(2.9) 14(2.0) 26(3.8) 5(2.1)
Door-to-needle time within 30 min 559(8.4) 181(5.9) 217(6.9) 54(7.5) 20.3 3 0.000
Door-to-needle time (min)† 50(27–100) 55(30–101) 49(24–102) 59(30–116) 10.7 3 0.013¥ (0.01, 0.02)¥
Door-to-balloon time (min)† 112(78–168) 109(73–156) 96(71–165) 81(48–124) 10.4 3 0.018¥ (0.01,0.02)¥





+Reason for no reperfusion includes refusal, missed fibrinolysis, and contraindication.
¥Kruskal-Wallis test with Monte Carlo level of significance (99% CI).
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groups in the world and also one of the regions with the
highest burden of CVDs [32]. Studies on South Asian
migrants in Western countries such as Canada, United
Kingdom (UK) and the United States of America (USA)Table 7 In-hospital clinical outcomes by ethnicity
In-hospital clinical outcomes Ethn
Malays Chinese
CCU Days‡ 3.5(2.8) 3.2(2.6)









Adjusted OR for mortality (95% CI)¥
STEMI 1 0.93 (0.74, 1.16)
NSTEMI/UA 1 0.71 (0.55, 0.91)
*Others: Indigenous (Orang Asli), Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban (m





+TIMI (Thrombolysis In Myocardial Infarction) major bleeding involves a hemoglobin
or cardiac tamponade.
¥Binary multiple logistic regression; ORs adjusted for age and sex.documented significantly higher risks of CVDs with higher
morbidity and mortality than other ethnic groups
[10,14,33,34]. Previous mortality statistics and cross-
sectional surveys had confirmed that Indians have an in-
creased risk of CAD compared to other ethnic groupsic group F† χ2 df P§
Indians Others*
3.6(2.9) 3.2(2.5) 7.4 0.000
4.7(3.5) 4.9(3.7) 11.3 0.000




96(8.1) 30(8.2) 3.3 3 0.352
69(3.7) 15(5.4) 17.8 3 0.000
0.93 (0.66, 1.47) 0.99 (0.66, 1.47)
0.57 (0.43, 0.76) 0.78 (0.45, 1.34)
inor ethnic groups) and other non-Malaysians.
drop >5 g/dL (with or without an identified site) or intracranial hemorrhage
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http://www.biomedcentral.com/1471-2261/13/97[11,35]. A cardiovascular cohort study showed that ethni-
city plays a major role in CAD with Indian males found to
have three times the risk of CAD as compared to Malays
and Chinese in Singapore [36].
The mean age at presentation was 59.1 years among
all ethnic groups. In contrast to earlier registries from
developed countries, such as National Registry of Myo-
cardial Infarction (NRMI) (mean age 68 years) [37], Glo-
bal Registry of Acute Coronary Event (GRACE) registry
(53% aged ≥ 65 years) [38,39] and the Euro Heart Survey
I (EHS-ACS-I) (mean age 63.4 years) [40,41], our cohort
was characterized by a younger age at presentation. The
mean age was similar to the CREATE registry (58 years)
[42] and Saudi Project for Assessment of Coronary
Events (SPACE) registry (57 years) [43] that were conduc-
ted in India and Saudi Arabia, respectively. The age at
presentation discrepancy observed between the European
and Asian Registries should be investigated further to
establish risk factors that possibly contributed toward the
age difference.
Similar to ACS registries world-wide, the predominant
sex was male (more than two thirds) among all ethnic
groups. There were substantial differences between male
and female in the presentation, diagnosis, management
and outcome of CADs [44-47]. Most clinical trials have
enrolled primarily men and the women have been
under-represented in CAD clinical trials; further re-
search involving larger female cohorts is required.
Further, at participating centers, a lower proportion of
women were found to have ischemia during the course of
routine clinical care, and screening tests for ischemia were
less predictive of CAD in women than those in men [48].
The patients’ risk factor profiles differed significantly
among the ethnic groups. For example, Malays showed
significantly highest mean BMI. Chinese patients had
the highest proportion of hypertension and hyperlipid-
emia. On the other hand, Indians had the highest mean
for WC and the highest proportion for DM and family
history of premature CAD. Others had significantly
highest proportion of smokers. The WC recorded
among all ethnic groups was generally higher than the
mean WC of Malaysians [49]. The finding of high WC
among Indians was similar to those previously reported
in the Malaysian National Health and Morbidity Survey
III [49]. The finding of high prevalence of BMI among
all ethnic groups with ACS was similar to another
Malaysian prevalence study on overweight and obesity
among non ACS population [50]. Higher BMI among
Malays with ACS was also consistent with the national
study on obesity among Malaysians according to ethni-
city [51]. This explains the relationship between high
BMI and higher occurrence of ACS in the general popu-
lation [52]. The results suggest that a higher proportion
of patients with ACS also have metabolic syndrome ascompared to the general population [53,54]. DM has
been found to be more common in Indians. This finding
was consistent with previous multi-center registries and
studies in Singapore [55], Trinidad [35], Fiji [56], USA
[57] and UK [33,58]. A study in Canada by the Study of
Health Assessment and Risk in Ethnic Groups (SHARE)
investigators also found that Indians had more plasma
glucose and lipid abnormalities compared to Europeans
and Chinese [16]. Indians also have higher past history
of CVDs and family history of MI compared to other
ethnic groups [57]. Generally, our patients had high
prevalence of coronary risk factors at presentation
among all ethnic groups. These findings were similar to
an earlier publication using NCVD [59], Singapore
population [60], Iranian population [61], Saudi Arabia
population [62], and in developing countries [63].
ACS
The proportion of STEMI among all ethnic groups
(38.8–58.3%) was higher compared to earlier ACS
registries in developed countries: GRACE (30.0%) [38],
EHS-ACS-I (42.3%) [40], NRMI (40.0%) [64], Euro Heart
Survey II (EHS-ACS-II) (34.5%) [65] and Canadian
Acute Coronary Syndrome Registry (27.7%) [66]. Higher
proportion of STEMI compared to NSTEMI and UA in
NCVD was similar to those in the CREATE registry
(47.3–71.4%) [42]. In the CREATE registry, poorer
socio-economic group of patients recorded a higher pro-
portion of STEMI in India. This finding could possibly
explain why Others (indigenous ethnic groups), who
generally belong to the lower socioeconomic status, re-
corded a higher proportion of STEMI.
Lipid profile, fasting blood glucose
Our findings on serum lipid were consistent with previ-
ous studies on Indian populations living in UK and USA.
Generally, Indians have lower HDL cholesterol than
whites or Afro-Caribbean populations but do not have
higher total or LDL cholesterol than other races [67-69].
Hospital medications
Results indicated high use of Aspirin, Beta-blockers,
LMWH and Statins among all ethnic groups was in line
with the Clinical Practice Guidelines [26,28,70] and
comparable to those in developed countries. Religious
practice could be a factor to explain the lower use of
LMWH (containing porcine-related material) among
Malays as the overwhelming majorities are Muslims
compared to other ethnic groups.
Invasive therapeutic procedures and culprit artery
On invasive therapeutic procedures, the rate of PCI and
CABG in our registry was lower than those reported in
developed countries [38,40,65,66]. Our results showed
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http://www.biomedcentral.com/1471-2261/13/97disparities existed in the use of medications, PCI and
CABG among ethnic groups. The finding of LAD artery
as the most common culprit artery was similar to those
of Yadav et al. [71] and Deshpandey and Dixit [72].
Treatment of STEMI
In STEMI, timely delivery of reperfusion therapy can re-
duce mortality; therefore, guidelines recommend fibrinoly-
sis within 30 min (door-to-needle time) and primary PCI
within 90 minutes (door-to-balloon-time) [25,28]. Primary
PCI has been proven better than fibrinolysis in treating
STEMI [73,74] and timely administration of fibrinolytic
therapy significantly reduces mortality [75]. In STEMI,
despite majority of patients who received reperfusion ther-
apy, the rate of primary PCI was lower and the use of fibri-
nolytics was higher among all ethnic groups as compared
to ACS registries in developed countries such as GRACE
[38], EHS-ACS-I [40] and EHS-ACS-II [65]. In the fibrin-
olysis subgroup, door-to-needle time among all ethnic
groups was longer than those recommended by the
American and European Guidelines [25,28] and the pro-
portion of patients achieving less than 30 minutes of door-
to-needle time was low. This is one of the main concerns
of our study that illustrated suboptimal care in treating
STEMI. Streptokinase, the less-fibrin specific (less effect-
ive) fibrinolytic agent as compared with fibrin-selective fi-
brinolytic agents [76] was commonly used among all
ethnic groups. Higher proportion of Chinese received less
reperfusion therapy than other ethnic groups; however,
the reasons for these discrepancies were unclear.
In the implementation of evidence-based reperfusion
strategies, doctors have to make the best decision to allo-
cate limited resources to patients who are at highest risk
and hope to obtain the largest benefit. Many studies have
found differences in the delivery of cardiac care and reper-
fusion procedure among different ethnic groups in ACS
[77-79]. Earlier studies of ethnic variation in the treatment
and outcome of ACS in USA showed that non-whites had
longer door-to-needle time in the treatment of AMI [80]
and were less likely to undergo invasive cardiac procedures
[81,82]. However, this finding was controversial in other
clinical trials [83]. Research has shown that by implement-
ing a national quality improvement program, it is possible
to reduce or eliminate the differences in care by ethnicity
[84]. Considerably more effort and resources will be
granted to improve the reperfusion strategies in developing
countries like Malaysia for all patients regardless of their
ethnic origin. Adherence to clinical practice guidelines has
shown to improve quality of care and associated with sig-
nificant reduction in in-hospital mortality rates [85].
In-hospital clinical outcomes
In developed countries, STEMI mortality rates were re-
ported as 4.3–4.4% in NRMI [86], 7.0% in the GRACERegistry [38], 7.0% in the EHS-ACS-I [40] and 2.4% in
the Canadian Acute Coronary Syndrome Registry [66].
In the NCVD, higher STEMI mortality rate (8.1–10.1%)
in comparison with developed countries could be ex-
plained by lower use of primary PCI, higher use of less
effective fibrinolytic agent (Streptokinase) and delay in
door-to-needle time among all ethnic groups. In
addition, LAD artery involvement as the main culprit
vessel (>56%) among all ethnic groups could have con-
tributed towards a less favorable outcome as reported
earlier by Thanavaro et al. [87].
Interestingly, despite the fact that disparities exist in
risk factors, clinical presentation, medical treatments
and invasive management, there was no statistically sig-
nificant difference in STEMI mortality among all ethnic
groups. However, there are limitations in the analysis of
mortality outcome comparing different ethnic groups
and we advise caution in its interpretation. Firstly, it was
an in-hospital mortality of STEMI and NSTEMI/UA of
both genders and all age groups. As for ACS, many stud-
ies had shown higher mortality in women [88,89] and
older patients [39,41,90]. Hence, the mortality outcome
analyzed in this method may have over or underesti-
mated the differences between age groups and across
genders. Secondly, we used in-hospital all-cause mortal-
ity as an end point in order to minimize event misclassi-
fication. Results for cardiac-specific mortality may be
different for present results. Caution should, therefore,
be observed in comparing results with those from other
national registries or clinical trials.
On the basis of the risk factor profiles across all ethnic
groups, it would seem unreasonable for Malays to have
higher NSTEMI and UA mortality. It would seem that
higher mortality in Malays can be partly explained by
the higher proportion of Malays receiving lower rates of
PCI compared to other ethnic groups. Other possible ex-
planations include greater cigarette consumption and
higher BMI among Malays.
Earlier observational studies locally and elsewhere
have shown a higher proportion of deaths in Indians
with IHD compared to other ethnic groups [11,35,91].
The finding of lower in-hospital mortality in NSTEMI/
UA among Indians in our study contradicted with previ-
ous studies for unexplained reasons.
There were evidences that bleeding risk in ACS differs
in different type of ACS, reperfusion therapy and ethnic
groups [92]. Registry data [92], prospective study [93]
and randomized controlled trials (RCT) [94] of devel-
oped countries in ACS patients reported that the major
bleeding risk was between 4.6–10.9%. Compared to de-
veloped countries, major bleeding in NCVD was gener-
ally low among all ethnic groups (0.2–0.7%) and this
finding was similar to those in the ACS Registry in India
(0.2–0.3%) (CREATE) and Middle Eastern countries
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ing is intriguing and possibly could be explained by the
lower use of invasive cardiac procedures among all eth-
nic groups as compared to those in developed countries.
Strengths and limitations
The main strength of this study is the collection of data
from multi centers to represent a complete and unse-
lected group of patients in a real-world setting. Unlike
restricted populations recruited in RCTs which tend to
exclude high risk patients, the NCVD collects data on
the full spectrum of ACS patients from a nationwide
perspective. We gain insight into ACS patients that were
not included in RCTs. We use a standard method across
all ethnic groups in collecting data to avoid bias.
Several limitations of our study should be noted. Firstly,
misclassification of ethnicity can occur as ethnicity was
self-reported and mutually-exclusive. Secondly, the possi-
bility of selection bias despite our attempt to include hos-
pitals in different regions of the country. Many private
hospitals with significant number of ACS admissions pos-
sibly with a different ethnic distribution did not participate
in this registry. Ethnic minorities living in remote areas
had difficulty accessing the health facilities and therefore
could have been under-represented in this study. Thirdly,
there may have been underreporting of risk factors such
as cigarette smoking and past medical history as these
measures were self-reported and this may subject to bias.
Furthermore, statistical differences are frequently ob-
served in a large number of subjects but may not be
clinically meaningful. In studies with large patient enrol-
ment, small differences between groups will be highly
significant by conventional use of the p values, and the
clinical importance of these differences can only be
judged with clinical insight.
Conclusions
There are two major implications of our study. First, we
have shown interesting facts about the differences and
similarities of demographic, risk profile, ACS stratum,
treatment and outcome among different ethnic groups.
Second, our study establishes a critical understanding of
disease spectrum, drug usage, invasive procedures, clinical
outcomes, and the overall quality of care provided to ACS
patients in Malaysia. In addition, the NCVD provides in-
sights and forms the basis for clinical investigators to de-
sign future clinical trials. The NCVD also enables
clinicians and health care administrators to compare
disease-specific patterns, management and outcomes
which might lead to changes in national health priorities
or strategies of disease management.
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